ArticleHuman cell2026
Unveiling TNFRSF19: a novel tumor suppressor targeting endoplasmic reticulum stress and LGR5/Wnt/β-catenin in cervical cancer.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
TNF Receptor Superfamily Member 19 (TNFRSF19) has been implicated in the advancement of several types of cancer. However, its function and mechanism in cervical cancer (CC) remain unclear. Additionally, while ER stress is proposed as a therapeutic target in cancer, its relationship with TNFRSF19 in CC is unknown. This study aimed to investigate the role and underlying mechanisms of TNFRSF19 in CC. The expression of TNFRSF19 was investigated utilizing the GEPIA database and subsequently validated in 35 paired clinical CC tissue samples. The impact of TNFRSF19 overexpression on cellular proliferation, apoptosis, and endoplasmic reticulum (ER) stress was evaluated in C33A and HeLa cell lines through CCK-8 assays, colony formation assays, and flow cytometry. The interaction between TNFRSF19 and LGR5, along with its inhibitory effect on the Wnt/β-catenin pathway, was analyzed using co-immunoprecipitation (Co-IP), immunofluorescence, and western blotting techniques. Additionally, an in vivo xenograft tumor model in nude mice was developed to substantiate the tumor-suppressive function of TNFRSF19. TNFRSF19 expression was significantly reduced in CC tissues and cell lines. TNFRSF19 overexpression substantially inhibited cell proliferation and colony formation, and induced apoptosis in vitro, while also suppressing tumor growth in vivo. Mechanistically, TNFRSF19 facilitated apoptosis through the activation of ER stress and directly interacted with LGR5 to inhibit the LGR5/Wnt/β-catenin pathway. The pro-apoptotic and tumor growth-inhibitory effects induced by TNFRSF19 were diminished by the ER stress inhibitor 4-phenylbutyric acid (4-PBA). Moreover, the inhibitory effect on cell proliferation mediated by TNFRSF19 was effectively reversed upon the restoration of LGR5 expression. This study demonstrates that TNFRSF19 functions as a novel tumor suppressor in CC by activating ER stress and inhibiting the LGR5/Wnt/β-catenin pathway, highlighting its potential as a therapeutic target for CC treatment.
Indexed as
Identifiers
41840262What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.